BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014.

The company was founded in 1986 by Charles E. Bugg and John A.

[2] In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange.

[3] In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006.

[4] In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania.